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Numerous neurological disorders including fragile X syndrome, Down syndrome, autism,
and Alzheimer’s disease are co-morbid with epilepsy. We have observed elevated seizure
propensity in mouse models of these disorders dependent on diet. Specifically, soy-based
diets exacerbate audiogenic-induced seizures in juvenile mice.We have also found potential
associations between the consumption of soy-based infant formula and seizure incidence,
epilepsy comorbidity, and autism diagnostic scores in autistic children by retrospective
analyses of medical record data. In total, these data suggest that consumption of high lev-
els of soy protein during postnatal development may affect neuronal excitability. Herein, we
present our theory regarding the molecular mechanism underlying soy-induced effects on
seizure propensity. We hypothesize that soy phytoestrogens interfere with metabotropic
glutamate receptor signaling through an estrogen receptor-dependent mechanism, which
results in elevated production of key synaptic proteins and decreased seizure threshold.
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INTRODUCTION
Soy was first grown in the United States in the 1760s. This legu-
minous plant is native to East Asia and related to peas, alfalfa,
and clover. Soybeans are the seeds of the soy plant and contain
high levels of protein with significant quantities of the essential
amino acids. Soybeans are the only plant source of complete pro-
tein containing all 20 amino acids. Soybeans are ground to produce
soybean oil and soybean meal. Soybean oil is used in food products
such cooking oil and in industrial products including plastics and
biodiesel fuel. Soybean meal, the protein-rich fraction, is used in
food, beverages, and condiments for human consumption as well
as in animal feed. According to the American Soybean Association,
soybeans were planted on over 75 million acres in the United States
in 2012 and were the second largest cash crop with over 3 billion
bushels produced. This vegetable protein is used extensively by the
food industry in the United States as an additive in nearly all types
of foods. Soy protein is also sold as a dietary supplement and is
the key ingredient in soy-based infant formulas.
Soy has been purported as a dietary therapy for cardiovas-
cular disease, type 2 diabetes, osteoporosis, hormone-dependent
cancers, and the symptoms of menopause, but medical research
has been inconclusive in substantiating many of these claims.
The FDA recommends that 25 g/day of soy protein, as part of a
diet low in saturated fat and cholesterol, may reduce the risk of
heart disease; however, the Nutrition Committee of the American
Heart Association reviewed 22 randomized clinical trials compar-
ing isolated soy protein containing isoflavones to milk and other
proteins on LDL-cholesterol levels and found the average effect
was only 3% (1). They found no benefit regarding HDL choles-
terol, triglycerides, or blood pressure. A subsequent meta-analysis
found a 4.2–5.5% reduction in LDL cholesterol, a 3.2% increase
in HDL cholesterol, and a 10.7% decrease in fasting triacylglycerol
levels suggesting that daily consumption of 15–30 g of soy signifi-
cantly improved serum risk factors for cardiovascular disease (2).
A meta-analysis of soy product consumption in patients with type
2 diabetes mellitus found that soy protein intake was beneficial
in diabetic patients in terms of serum lipids, but there were no
significant effects on fasting glucose, insulin, or glycated hemoglo-
bin levels (3). Osteoporosis studies indicate that soy isoflavones
stimulate bone formation, inhibit bone resorption, and increase
bone mineral density, resulting in attenuation of bone loss in
menopausal women (4–9), albeit there are reports of only slight
or no clinical effects (10). Cancer meta-analyses indicate that the
consumption of soy or soy isoflavones is associated with reduced
prostate cancer (11–14), gynecological cancers (15), and possi-
bly breast cancer (16–21). There is no conclusive evidence that
soy phytoestrogens reduce hot flashes associated with menopause
(22–24). Overall, the literature contains many conflicting reports
regarding the health benefits of consuming soy and phytoestro-
gen supplements. While the FDA has authorized a health claim
linking the consumption of soy protein with a reduced risk of coro-
nary heart disease, the agency also lists soy in its poisonous plant
database with warnings regarding goiter, growth problems, amino
acid deficiencies, mineral malabsorption, endocrine disruption,
and carcinogenesis (25).
Perhaps the most controversial use of soy is in soy-based infant
formulas. The current position of the American Academy of Pedi-
atrics is, “There is no conclusive evidence from animal, adult
human, or infant populations that dietary soy isoflavones may
adversely affect human development, reproduction, or endocrine
function (26).” And the national toxicology program (NTP) Cen-
ter for the Evaluation of Risks to Human Reproduction (CERHR)
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found that, “The overall evidence was considered insufficient to
reach a conclusion on whether the use of soy infant formula pro-
duces or does not produce developmental toxicity with infant
exposure in girls or boys at recommended intake levels” (27). In
other words, there is not conclusive evidence that soy-based infant
formulas are safe. Based on market sales, 12% of infant formulas
in the United States are soy-based (27). Approximately 20–25%
of infants receive some soy-based formula during their first year,
but there is no data regarding how many are exclusively fed soy-
based formula (28). While there may be health benefits for adults
associated with the consumption of soy, this natural product holds
potential danger for children. Soy products are rich in phytoestro-
gens, which are natural plant chemicals that have estrogenic and
anti-estrogenic properties. The effects of phytoestrogens on fetal
and early childhood development have not been extensively stud-
ied (29–31). Rodent studies indicate that the placenta acts as a sink
for phytoestrogens, and that while transport of phytoestrogens
across the placenta is inefficient, low levels are found in the fetus
and are sufficient for activation of estrogen receptor beta (ERβ)
(32). A 4-month-old infant fed soy formula would be exposed
to 4.5–8 mg/kg/day of soy phytoestrogens (33, 34), which is 6–11
times the dose necessary to exert hormone-like effects in adults
(33). In placental mammals, the fetus is continuously exposed to
high levels of estrogen from the placenta and the mother. Environ-
mental exposure to phytoestrogens during this period is expected
to disrupt the function of the natural steroid hormones.
In summary, the safety of long-term soy phytoestrogen con-
sumption remains a controversy. Our research, which is reviewed
below, suggests that soy-based diets are associated with increased
seizure susceptibility in both rodent and human models of neuro-
logical disease. In this Hypothesis and Theory paper for the Diet
and Brain Disorders Research Topic of Frontiers in Neurology,
we consider the potential molecular mechanism underlying soy-
associated effects on seizure propensity. We hypothesize that soy
phytoestrogens interfere with metabotropic glutamate receptor
(mGluR) signaling through an estrogen receptor (ER)-dependent
mechanism, which results in elevated production of key synaptic
proteins and decreased seizure threshold in genetically suscepti-
ble individuals. First, we summarize our recent research, which
implicates soy protein consumption with increased seizure sus-
ceptibility. Second, we discuss the potential implications of these
findings for infants fed soy-based infant formulas. Third,we review
published work in the areas of fragile X syndrome (FXS), mGluR5
signaling, and ER signaling that forms the foundation for our
hypothesis. Fourth, we present our working model regarding the
molecular mechanism underlying soy-induced seizure activity.
And finally, we discuss alternative hypotheses that could explain
soy-induced health effects.
SOY CONSUMPTION, SEIZURES, AND AUTISM
Our research has examined audiogenic-induced seizure (AGS)
incidence after chronic treatment with mGluR5 antagonists in sev-
eral transgenic mouse lines (35, 36). In pursuit of these objectives,
we incorporated the mGluR5 antagonist fenobam into a purified
ingredient, soy-free diet that was matched to our standard lab
chow (Purina 5015) for protein, fat, and carbohydrate content.
We chose to incorporate the drug into a soy-free diet because
FIGURE 1 | Soy-free diet reduces seizure propensity in several strains
of mice including Fmr1KO (FXS mouse model that lacks FMRP
expression),Tg2576 (Alzheimer’s disease mouse model that
over-expresses the humanAPP695 gene with the Swedish familial
mutation), andTs65Dn (Down syndrome mouse model that is trisomic
for chromosome 16 carrying theApp gene) (38). These mouse models of
neurological disease and WT littermates were conceived and maintained on
soy-based Purina 5015 chow. At age P18, pups were left on the Purina 5015
(black bars) or transferred to a purified ingredient, soy-free diet (D07030301,
white bars) for 3 days prior to seizure testing. Statistical significance
between mice of the same genotype but fed different diets was determined
by Barnard’s exact test (two-tail) and is denoted by a star (P ≤0.05).
Purina lab chows are grain based and nutrients vary from lot
to lot (37). Surprisingly, chronic feeding with the soy-free diet
alone (no fenobam added) (D07030301) for 3 days prior to seizure
testing drastically attenuated AGS in multiple mouse lines includ-
ing Fmr1KO (FXS), Tg2576 (Alzheimer’s disease), and Ts65Dn
(Down syndrome) (38) (Figure 1). We hypothesized that a longer
treatment period might further reduce seizure susceptibility and
assessed seizures in Fmr1KO mice conceived and maintained on
D07030301 until AGS testing at postnatal day 21. We found a sim-
ilar AGS rate as the 3-day feeding regimen. Thus, a soy-based diet
drastically influences seizure susceptibility in mice.
Purina-type lab chows are grain based with their protein con-
tent derived from soybeans (37). Soybeans are rich in phytoe-
strogens, “plant estrogens,” which can be transferred to offspring
through the placenta as well as maternal milk. The protein source
for the soy-free diet was casein instead of soybean-based, and thus,
it did not contain any phytoestrogens. To determine if the AGS
phenotype resurfaced in mice conceived on soy-free diet and later
exposed to soy, Tg2576 mice born to parents maintained on the
soy-free diet were weaned onto Purina 5015 at P18 and tested
for seizures at P21. There was a statistically significant increase
in seizures (36%, P ≤ 0.05) in the Tg2576 fed Purina 5015 for
3 days. We hypothesized that soy phytoestrogens were the seizure-
promoting constituent in the Purina 5015. Soy protein is rich in
a type of phytoestrogen called isoflavones, which are bioactive
compounds structurally similar to the female hormone estro-
gen. Isoflavones can exert biological activity by mimicking the
effects of mammalian estrogens and thus disrupt the endocrine
cycle. The three most prevalent isoflavones in soy are genistein,
daidzein, and glycitein. Hence, we tested the effects of individual
isoflavones on seizures by supplementing the soy-free diet with the
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two most prevalent isoflavones, genistein, or daidzein, at 0.75 g/kg
feed, which is within the concentration range of isoflavones natu-
rally found in soy products (39, 40). Mice were bred on the soy-free
diet and at P18 weaned onto daidzein- or genistein-supplemented
diets for 3-days prior to AGS testing at P21. Daidzein signifi-
cantly increased wild running in wild-type mice (39%, P ≤ 0.01),
although 3 days feeding was not sufficient to induce a statistically
significant increase in AGS (21%, P ≤ 0.1). Chronic dosing studies
are currently underway. Genistein, or the combination of genis-
tein and daidzein, did not alter wild running, AGS, or death rates
suggesting that genistein may counteract the seizure-promoting
effect of daidzein and that the ratio of the isoflavones in soy may
determine seizure propensity (38).
In addition to our studies, the Hosseini laboratory in Iran
has studied the effect of soy extract on pentylenetetrazol (PTZ)-
induced seizures in rats (41, 42). First, they treated rats with
repeated low doses of PTZ (40 mg/kg body weight) over 14 days in
conjunction with low (20 mg/kg body weight) and high (60 mg/kg
body weight) doses of soy extract 30 min before each PTZ injec-
tion. Both the low and high doses of soy extract elicited higher
seizure scores in ovariectomized (OVX) rats as well as signifi-
cantly decreased latency times to minimal clonic seizures (MCS)
and generalized tonic-clonic seizures (GTCS) (42). Second, they
treated male, female, and OVX female rats with high and low doses
of soy extract for 14 days followed by injection of a single dose of
PTZ (90 mg/kg body weight). They found that the soy extract
decreased the latency times to MCS and GTCS in the male and
OVX female rats but not in the female rats (41).
A literature search of the terms “soy” and “seizure” produces
very few studies. In humans, there are several case reports involv-
ing infants with seizure phenotypes in response to consumption of
a defective soy formula (Israel study) or who developed micronu-
trient deficiencies due to soy formula (Canadian study). The Israel
study was a follow-up study of seven Israeli, female children, age
5–6 years, with severe epilepsy as a result of thiamine deficiency in
infancy caused by a defective soy-based formula (43). Their find-
ings indicated that severe infantile thiamine deficiency might result
in epilepsy. The seizures were refractory to most antiepileptic drugs
with four children having uncontrolled seizures and all children
exhibiting mental retardation and brainstem dysfunction. The
Canadian study reported on three case articles of infants present-
ing with hypocalcemic seizures during the winter months while
being fed soy formula (44). The study population included three
infants with different ethnic backgrounds and living in different
geographical regions of Eastern Canada. All of the subjects were
male and 6 week- to 2-months old and presented with hypocal-
cemic seizures attributable to vitamin D deficiency. Laboratory
results were consistent with vitamin D deficiency despite receiving
daily recommended intake levels.
There have been studies examining cognitive and reproduc-
tive development in infants fed soy-based infant formula. Malloy
and Berendes tested 9- to 10-year-old-children who had been
fed soy-based infant formula or human milk during their first
year of life and found no difference in IQ, behavioral problems,
learning impairment, or emotional problems (45). A study by
Strom and colleagues surveyed adults age 20–34 years old who
had participated as infants in controlled feeding studies between
1965 and 1978 (46). The study population included 811 sub-
jects including males (n= 120) and females (n= 128) who had
been fed soy-based infant formula. The outcomes were that no
correlation was found between infant formula use and educa-
tion level, but women in the soy cohort reported longer duration
of menstrual bleeding (about 8 h) and greater discomfort with
menstruation. The soy cohorts also had a higher reported use
of asthma or allergy drugs and greater tendency toward seden-
tary activities. The consumption of soy-based infant formula has
also been associated with breast development (47) and premature
thelarche (48).
There have been several rodent studies assessing the effect of
soy phytoestrogens on seizures, which are described above. The
problem with studying soy in rodents is that they metabolize soy
isoflavones differently from humans. Thus, the data may not be
generalizable between species. It should be noted that infants can
efficiently digest, absorb, and excrete genistein and daidzein from
soy-based infant formulas (49). Urine was collected from dispos-
able diapers (3–5 diapers worn during a 24-h period) of infants
(4 received soy-based formula and 25 received cow milk-based
formula). Isoflavones were extracted from the diapers every 1–
2 weeks from a starting age of 2–6 weeks and continuing until
16 weeks of age and detected by HPLC. Isoflavone (genistein plus
daidzein) levels remained constant at 3.2± 0.2 mg/kg body weight
regardless of age. Rodents conjugate isoflavones less efficiently and
thus have higher circulating concentrations of biologically active
forms (50). With this caveat noted, studies in rats and mice have
demonstrated that soy increases seizure propensity. In addition
to the aforementioned rodent studies, the effects of soy have been
studied in monkeys and in vitro. Dietary soy is associated with epi-
genetic changes in monkeys such that overall methylation in liver
and muscle tissue was increased when switching from a soy-based
to casein-based diet (51). At high doses, genistein and daidzein are
toxic to primary neuronal cultures (52).
Overall, a soy-based diet significantly increases seizure propen-
sity in genetically susceptible mice and daidzein is likely a con-
tributing factor. The amount of daidzein consumed per body
weight per day by juvenile mice is comparable to the daily
isoflavone intake of infants fed soy-based formula (34, 53) sug-
gesting that these findings could have important clinical relevance.
Hence, we conducted a retrospective analysis of seizure inci-
dence in autistic children fed soy- versus casein-based infant
formula. Seizures are a prevalent phenotype in autism (21–38%)
(54, 55). We utilized medical record data from the Simons Foun-
dation Autism Research Initiative – Simons Simplex collection
(SFARI-SSC) to assess seizure incidence in autistic children fed
soy-based versus other infant formula. There were data available
for 1949 subjects (87% males). We found a 2.6-fold increase in
the incidence of febrile seizures and a 4.8-fold increase in the inci-
dence of simple partial seizures in autistic children fed soy formula
(56) (Table 1). The soy-based formula was not associated with
statistically higher rates of infantile spasms, atonic (drop attack),
grand mal (generalized tonic clonic), petit mal (absence), or com-
plex partial seizures. There was a 2.1-fold increased incidence of
epilepsy. In aggregate, these data demonstrate that a soy-based
diet is associated with increased seizure incidence in both mouse
models of neurological disease and in autistic children. These data
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Table 1 | Prevalence of seizures in autism subjects dependent on soy
formula.
Phenotype Soy Non-soy
Febrile seizures (%) 4.2**
††
1.6
Infantile spasms (%) 0.60 0.063
Atonic seizures (%) 0.30 0.13
Grand mal seizures (%) 1.2 1.9
Petit mal seizures (%) 3.3 2.0
Simple partial seizures (%) 1.2
†
0.25
Complex partial seizures (%) 0.60 0.38
Epilepsy diagnosis (%) 3.6*
†
1.7
Minimum number of subjects per cohort=330 (soy) and 1563 (non-soy).
*P≤0.05 and **P≤0.01 as determined by the Pearson’s uncorrected chi-squared
test.
†P≤0.05 and ††P≤0.01 as determined by Fisher’s exact test (two-tail).
raise important questions regarding the neurological side effects
of a soy-based diet during postnatal development.
We also assessed developmental milestones and autism testing
scores in the SFARI autism population dependent on soy-based
infant formula. There were no statistically significant differences
in developmental milestones (age first walked, age of first sin-
gle word, or age of first phrase) dependent on soy or non-soy-
based infant formula use. We did find exploratory associations
between the consumption of soy-based infant formula and several
autistic behaviors as assessed by sub-score and line-item analy-
sis of the aberrant behavior checklist (ABC), autism diagnostic
interview-revised (ADI-R), and autism diagnostic observation
schedule (ADOS) (57). It is important to note that these find-
ings were exploratory in nature as the SFARI data collection
protocol was neither specifically designed to assess the effects
of infant formula on autistic behaviors nor powered to detect
multiple hypotheses based on line-item analyses of diagnostic
tests.
There are limitations to the retrospective human data described
above including declarative data regarding the epilepsy diagnoses,
lack of data regarding potentially confounding issues, and less
female subjects than male. A diagnosis of epilepsy was defined as
either a specific report of epilepsy on the ADI-R or at least two
seizures on the medical record history report, which are based on
parental recall. A neurologist did not verify the diagnoses; how-
ever, NINDS considers detailed medical history reports of seizure
history one of the best methods available to identify if a person has
epilepsy as well as the type of seizures. Recall bias regarding infant
formula usage is not an expected problem as parents typically
switch formulas for very specific reasons such as gastrointesti-
nal problems or allergies. There are confounding issues associated
with the consumption of soy-based infant formula that will need
to be addressed in future, prospective studies such as the reasons
the infants were fed soy-based formula and the duration of feeding
with the soy-based formula. It is possible that soy is a surrogate
marker for an underlying condition that lowers seizure threshold.
For example, infants that are fed soy-based infant formula due to
cow milk protein allergies could be more vulnerable to illnesses
associated with fever-induced convulsions. We can not make a
definitive conclusion regarding this scenario based on retrospec-
tive data; however, in the SFARI study population utilized for our
analysis, no subjects reported both allergies and febrile seizures. In
accordance with current autism prevalence rates, there were sig-
nificantly less female subjects than males in the study. Despite the
lower number of females, the use of soy-based infant formula was
associated with febrile seizures in females. A larger female cohort
is required to confirm whether the use of soy-based infant formula
is associated with epilepsy comorbidity in autistic girls.
IMPLICATIONS OF SOY-BASED INFANT FORMULAS ON
CHILDHOOD NEUROLOGICAL DEVELOPMENT
The presented data suggest that the consumption of soy-based
diets is associated with reduced seizure threshold in several mouse
models of neurological disease as well as in a vulnerable popu-
lation of children diagnosed with autism. These results require
prospective evaluation regarding the effects of soy on childhood
development particularly in infants genetically predisposed to
seizure disorders. Many developmental disabilities are co-morbid
with seizures and epilepsy including FXS, autism, and attention
deficit/hyperactivity disorder (ADHD).
Fragile X syndrome is the most common form of inherited
mental retardation and the leading known genetic cause of autism.
This X chromosome-linked disorder is clinically characterized by
highly variable intellectual disability (overall IQ< 70), autistic-
like behavior, seizures, macrocephaly, and macroorchidism (58).
FXS results from a mutation in a single gene on the X chromo-
some, FMR1. In the majority of cases, a >200 copy trinucleotide
(CGG) repeat expansion in the 5′-UTR of the FMR1 gene (59) is
associated with transcriptional silencing of the FMR1 promoter
and loss of expression of fragile X mental retardation protein
(FMRP) (60). FMRP is a multi-functional mRNA binding protein
that is involved in the transport, localization, and translational
regulation of mRNA ligands and is required for normal dendrite
development. FMRP expression is absent or greatly reduced in FXS
and many FXS phenotypes are manifested in Fmr1KO mice, which
lack expression of FMRP. In the preceding section, we demon-
strated an increased incidence of AGS in a mouse model of FXS
in response to a soy-based diet. FXS is a family of disorders also
including the FMR1 premutation disorders fragile X-associated
primary ovarian insufficiency (FXPOI) and fragile X-associated
tremor/ataxia syndrome (FXTAS). There is an increased preva-
lence of seizures in boys with the FMR1 premutation co-morbid
with autism spectrum disorders (ASD) (61).
Autism is a cluster of complex neurobiological disorders that
normally present in the second or third years of life. The core
features include impairments in social interaction and communi-
cation and repetitive stereotyped behavior. Many autistic children
are mentally retarded and half exhibit marked delay in motor
milestones. ASD are estimated to occur in 1 in 88 children with
prevalence 4.7-fold higher in males (62). The etiology of autism is
not known but genetic as well as environmental factors likely affect
the severity of symptoms (63–65). For example, autism is highly
co-morbid with other developmental disorders such as FXS where
67% of males and 23% of females meet the diagnostic criteria for
ASD (66). Epilepsy is highly co-morbid in autism with a prevalence
of 21.4% in autistic subjects with intellectual disability and 8% in
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subjects without intellectual disability (67). EEG abnormalities
were found in 31% of children with ASD (68), and are associated
with language disorders (69). It has been proposed that epilepsy
drives autism in neurodevelopmental disorders (70, 71).
Attention deficit/hyperactivity disorder is the most common
neurobehavioral disorder diagnosed in children with a worldwide
prevalence of 5.3% (72) and a national prevalence of 9.0% (73).
ADHD is characterized by in attention, impulsivity, and hyperac-
tivity. The diagnostic and statistical manual of mental disorders-
fourth edition (DSM-IV) diagnosis requires the presence of six out
of nine specific behavioral and functional symptoms of inattention
or hyperactivity/impulsivity for a duration of at least 6 months,
with onset before age 7 years. ADHD is highly co-morbid with
ASD and epilepsy. Up to 70% of ASD cases (74) and 38% of chil-
dren with epilepsy exhibit ADHD (75–77). ADHD is significantly
more common among children with newly diagnosed epilepsy
than among controls suggesting that there is a common antecedent
for both conditions (78, 79).
Several factors could contribute to the comorbidity of epilepsy
with these developmental disorders, such as underlying brain
pathology, genetic susceptibility genes, and/or environmental and
dietary factors that exacerbate epileptiform activity. It is estimated
that there are over 350 autism susceptibility genes (80). Dietary
factors remain less well characterized. The prevalence of epilepsy
in patients with celiac disease is 5.5% (81). Elevated levels of man-
ganese are associated with neurocognitive deficits (82, 83), and
it has been proposed that soy-based infant formula may cause
ADHD due elevated manganese content (84). We hypothesize that
soy phytoestrogens are a dietary factor that increases epileptiform
activity, which leads to the development of ADHD and autism. In
Israel where there is widespread use of soy-based formula without
clinical indications (70% of children receive soy for >6 months)
(85), there is a high rate of ADHD (12.6%) (86). In the SFARI
autism population described in the previous section, we observe
a statistically significant increase in ADHD with the consumption
of soy-based infant formula (6.7% soy, 3.9% non-soy, 1.7-fold
increase, P = 0.04). Thus, the consumption of soy-based infant
formulas may be altering neuronal excitability and contributing to
the increased incidence and/or severity of neurological disorders.
FXS AND mGluR SIGNALING
Seminal work by Drs. Kim Huber and Mark Bear has shown that
excessive signaling through mGluR5 contributes to many of the
psychiatric and neurological aspects of FXS (87). Genetic reduc-
tion of mGluR5 in an Fmr1KO background (88) or pharmacologi-
cal treatment with an mGluR5 inhibitor (89–91) rescues many FXS
and autistic phenotypes. mGluRs belong to the G-protein-coupled
receptor superfamily. There are eight identified subtypes of mGluR
that have been classified into groups based on sequence homol-
ogy and signaling properties. Group 1 (mGluR1 and mGluR5) are
generally postsynaptic in location, couple to Gq, and activate phos-
pholipase C. mGluR5, which signals through FMRP, has been the
major target of drug discovery for FXS over the past decade (87).
The“mGluR theory of FXS”proposes that FMRP binds to synaptic
mRNAs and represses their translation. Upon mGluR5 activation,
FMRP is dislodged or inactivated, and translation proceeds. This
accounts for “regulated translation” at the synapse. In the absence
of FMRP, as in FXS, mGluR5-mediated translation is constitutive
and unregulated. Over the past two decades, there have been piv-
otal advances regarding the identification of downstream signaling
molecules and translational targets in the mGluR5/FMRP path-
way by academia as well as the development of numerous robust
mGluR5 inhibitors by pharmaceutical companies. However, there
is a paucity of knowledge regarding the upstream activators and
environmental factors that stimulate mGluR5 signaling. Based on
our preliminary data presented above, we hypothesize that estro-
genic compounds in soy stimulate mGluR5 signaling and thus
contribute to FXS pathogenesis.
ER SIGNALING AT THE SYNAPSE
The major “female” and “male” steroid hormones are classified
as estrogens and androgens, respectively. Both classes of hor-
mones are found in both genders but in different quantities.
The most predominant and potent estrogen is estradiol. Estra-
diol can be synthesized by the endocrine glands and secreted
into the bloodstream and thereby enter and stimulate target tis-
sues including the brain. Estradiol can also be synthesized locally
within the brain (92) de novo from cholesterol or derived from
testosterone by P-450 aromatase, also known as estradiol syn-
thase, through an aromatization reaction. Hippocampal neurons
produce P-450 aromatase and generate estradiol (93). Estradiol
acts on both the alpha and beta forms of ER, ERα and ERβ,
which are primarily localized in the cell nucleus where they act
as ligand-regulated transcription factors by binding to specific
estrogen response elements (ERE) on DNA, i.e., “classical ER sig-
naling.” However, accumulating evidence demonstrates that ERα
and ERβ are also found at cell membranes where they interact
with mGluRs to initiate cell signaling, i.e., “non-classical ER sig-
naling.”The Mermelstein laboratory has proposed the“ER/mGluR
hypothesis” to explain the rapid membrane actions of estrogen in
the nervous system. Their theory purports that direct protein–
protein interactions between ER and mGluRs allow estradiol to
signal through mGluRs. Upon estradiol binding to the ER, the
ER alters the conformation of mGluR, resulting in activation of
the downstream G-proteins and second messenger signaling with-
out the requirement for glutamate (94). Both ERα and ERβ are
detected on dendritic spines and axon terminals; however, ERβ
has more widespread localization to extranuclear sites suggest-
ing that this isoform may be more important in mediating rapid
estrogen signaling at membranes (95).
Soy phytoestrogens can act as endocrine disrupting chemicals
(EDC) (96), and the developing fetus and neonate are partic-
ularly vulnerable to their effects. EDC bind to ER and induce
ER-mediated gene expression and altered cell signaling. Peri-
and postnatal exposure to EDC are expected to disrupt the
hypothalamic–pituitary–gonadal axis (HPG axis), which is criti-
cal for the development of the reproductive and immune systems.
It has been hypothesized that premature activation of the HPG
axis is the cause of growth impairment in FXS (97). Thus, dietary
exposure to high levels of soy phytoestrogens during infancy could
negatively impact growth and development.
There is a paucity of studies regarding the effects of phytoe-
strogens on neuronal excitability. It is known that genistein is a
broad-spectrum tyrosine kinase inhibitor, and tyrosine kinases
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modulate synaptic plasticity and ion channel function. Genistein
has been shown to decrease neuron excitability in Aplysia sensory
neurons (98), 3,5-DHPG-induced membrane potential oscilla-
tions in striatal cholinergic interneurons (99), and excitability of
capsaicin-sensitive neurons from cultured rat trigeminal ganglion
neurons (100). Daidzein, which is a structural analog of genistein,
that does not possess protein tyrosine kinase inhibitor activity, also
decreases excitability but to a lesser extent than genistein (100).
Much remains to be learned regarding the effects of daidzein and
other phytoestrogens on neuronal excitability.
MELDING THE BEAR “mGluR THEORY OF FXS” WITH THE
MERMELSTEIN “ER/mGluR HYPOTHESIS”
An important, unanswered question regards how soy and/or soy
isoflavones affect neuron function. Both genistein and daidzein
inhibit GABAAR (101), which is the major inhibitory receptor in
the brain with roles in seizures, hyperactivity, learning and mem-
ory, and sleep/wake cycles. Alternatively, or perhaps concurrently,
soy isoflavones could affect neuronal function through mGluR5
signaling. We are exploring the hypothesis that soy phytoestrogens
such as daidzein promote altered mGluR5/ER/scaffolding protein
interactions, resulting in activated mGluR5 signaling, which leads
to increased epileptiform activity. This hypothesis developed from
our data described above demonstrating that dietary soy con-
sumption is associated with increased seizure incidence in Fmr1KO
mice (38) and in autistic children (56). These data in conjunction
with published reports demonstrating the interaction between ER
and mGluRs (102–105) suggest that soy phytoestrogens could
exacerbate mGluR5 signaling through an ER-dependent mech-
anism. Excessive levels of estrogenic compounds are predicted
to increase mGluR5 activation and downstream signaling, par-
ticularly in FXS where the FMRP translational brake is absent.
Thus, we propose that coupling the Bear “mGluR theory of FXS”
with the Mermelstein “ER/mGluR hypothesis” provides a plausi-
ble mechanism through which estrogenic compounds such as soy
phytoestrogens lower seizure threshold (Figure 2).
ALTERNATIVE HYPOTHESES
There are alternative hypotheses,which could explain how soy low-
ers seizure threshold including non-neuronal targets. For example,
understanding how the bacteria in the gut can affect the brain and
disease development is an emerging area of important research.
Bacteria in the gut have the potential to communicate with the
brain through the vagus nerve, by modulating the immune system
and/or by synthesizing novel neurotransmitters. It is known that
soy isoflavones affect the development of the intestines as well as
the make-up of the intestinal microbiota (106). There have been
two studies investigating the influence of soy-based infant formula
on the gut microflora in infants and/or children. The first study
found increased equol excretion in the soy group (19%) com-
pared to controls (5%) with elevated Bifidobacteria, Bacteroides,
and Clostridia bacteria in fecal samples from the soy group (107).
The second study found elevated Bifidobacteria species (B. adoles-
centis and B. infantis), which were not detected before commenc-
ing the soy-based formula (108). Bifidobaterium, Bacteriodes, and
Clostridium are among the human intestinal bacteria that can pro-
duce S-equol (109, 110), which is the biologically active metabolite
FIGURE 2 | Model of the hypothetical estrogen-induced signaling
pathway in neurons. (1) mGluR5 is a primary target for drug development
in FXS. (2) Cell stimulation causes clustering of mGluR5 receptors and
altered interactions with scaffolding proteins such as ER, caveolin and
Homer, which likely alter downstream signaling events. Daidzein or other
estrogenic compounds act as ER agonists. (3) mGluR5 is known to signal
through FMRP, a translational repressor. The absence of FMRP in Fmr1KO
cells results in constitutive, unregulated protein synthesis in response to
mGluR5 stimulation. (4) Altered mGluR5/FMRP signaling modulates the
synthesis of numerous synaptic proteins including APP,
microtubule-associated protein 1B (Map1B), and postsynaptic density
protein 95 (PSD95). Excessive production and accumulation of these
synaptic proteins contributes to elevated epileptiform activity and FXS
pathology.
of daidzein. Intestinal bacteria transform daidzein to equol in
humans that are equol producers. In Japan, Korea, and China,
up to 80% of people are equol producers, but as few as 25% of
people in North America and Europe can biotransform daidzein
into equol (110). Equol modulates expression of the BRCA1 and
BRCA2 breast cancer genes through an epigenetic mechanism,
resulting in decreased methylation (111). The effect of equol on
the methylation of neuronal genes has not been studied.
DNA and protein constituents of soy may also affect brain func-
tion. It was long thought that large macromolecules do not pass
directly from the digestive tract to the circulatory system. Emerg-
ing evidence is proving this paradigm false. Meal-derived DNA
fragments that are large enough to carry intact genes can avoid
degradation by the stomach acid, enter the human circulatory
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system, and be detected in blood plasma (112). In addition to
plant DNA,>90% of soybeans are genetically modified (GM) and
carry bacterial genes that can code for toxic proteins. It has been
estimated that if there were a 1 in a billion event of bacterial trans-
formation of GM DNA into gut bacterium and that with 1E15
bacteria in the human gut, one would potentially have 1 million
transformed bacteria in the intestines (113). These transformed
bacteria could constitutively express toxic proteins that could dam-
age the intestinal lining and cause disorders like celiac disease in
which peptides enter the circulatory system, stimulate antibody
production, and lead to autoimmune reactions that can affect
neurological function. The second most common GM trait codes
for a built-in pesticide produced by the soil bacterium Bacillus
thuringiensis (Bt).
Besides the macromolecular content of food (DNA and pro-
tein), chemical contaminants associated with soy have strong
potential to affect neurological and gut function. There is a strong
correlation between glyphosate usage and modern disease inci-
dence (114). Moms Across America and Sustainable Pulse con-
ducted a small study of lactating mothers across the United States.
They found high levels of glyphosate (76–166 mg/L) in 3 out of
10 breast milk samples. Glyphosate is sprayed on GM crops where
it acts as both a pesticide and herbicide, as well as on other crops
where it serves as a drying agent. This chemical that accumu-
lates in the soil is not easily degraded and is a known antibiotic
and endocrine disruptor. The Moms Across America was a small,
grassroots study to encourage future, controlled, scientific investi-
gation in this area. They could not afford to do a sensitive HPLC
analysis; thus, the prevalence of lactating mothers with glyphosate
in their breast milk could be higher than reported. There is one
anecdotal report of the negative detection of glyphosate coincid-
ing with the disappearance of inflammation and autism symp-
toms in an 8-year-old boy after 6 weeks on an organic diet and
2 weeks of reverse osmosis filtered water that tested negative for
glyphosate.
Finally, substantial evidence suggests that activation of the
immune system is associated with epilepsy (115, 116), and con-
sumption of soy and soy phytoestrogens is associated with acti-
vation of the immune system. Specifically, soy-based diets alter
cytokine production through an ERα-dependent pathway (117).
Mice fed high doses of daidzein (20 and 40 mg/kg/day) for 7 con-
secutive days exhibit enhanced non-specific immunity, humoral
immunity, and cell-mediated immunity (118). In addition, expo-
sure to environmental estrogenic compounds is implicated in the
increased prevalence of autoimmune disorders (119). Thus, soy
phytoestrogens and/or estrogenic pesticides associated with soy
may indirectly affect seizure propensity through modulation of the
immune system. This alternative hypothesis may occur through
disruption of the blood–brain barrier (BBB). Recent work from
Bargerstock and colleagues has shown that peripheral immu-
nity may regulate changes in the BBB through a BBB integrity
biomarker, S100B, which is detected in blood when the BBB is
compromised. Pilocarpine-induced status epilepticus is also asso-
ciated with increased circulating levels of S100B, which is thought
to trigger an autoimmune reaction (120). The original finding
that prompted the development of this hypothesis paper was an
association between febrile seizure incidence and the consumption
of soy-based infant formula (56). Fevers increase brain tempera-
ture in part through the release of inflammatory cytokines, which
are likely involved in the generation of febrile seizures (121). Thus,
interactions between the immune and nervous systems via a com-
promised BBB may affect seizure propensity with dietary factors
such as soy acting as an immune system trigger.
CONCLUDING REMARKS
In summary, soy infant formula has been used in the United
States since 1909 as an alternative for infants allergic to cow’s
milk. Published estimates of formula intolerance range from 2
to 7.5%; yet, about a quarter of infants are fed soy-based for-
mulas suggesting that non-standard, soy-based formulas are used
excessively (122). Understanding the health consequences of soy
phytoestrogens and modulating intake of these compounds during
pregnancy and infancy could potentially decrease the development
and/or exacerbation of childhood neurological disorders. There
have been no clinical trials examining the effects of soy-based for-
mulas on seizures or neurological development in infants with
developmental disabilities. These vulnerable groups may be more
susceptible to seizure-promoting ingredients in the diet. Prospec-
tive studies are required to validate the rodent and human analyses
described herein. There are numerous potentially confounding
factors that need to be addressed, most notably, the lack of data
regarding the age of initiation and the duration of feeding with
soy-based infant formula. Studies examining the health effects of
soy and soy phytoestrogens are further complicated by the fact
that Monsanto marketed GM soy in 1995. Glyphosate-tolerant
soybeans were genetically engineered to express the 5-enolpyruvyl
shikimic acid-3-phosphate (EPSP) synthase gene from Agrobac-
terium sp. (strain CP4), which infers resistance to Roundup®
herbicide. Currently, 93% of the soybean crops in the United
States are GM. Glyphosate, the active ingredient in Roundup®, is a
major environmental toxin implicated in the increased incidence
of autism, Alzheimer’s disease, cancer, and many other diseases
(114). Thus, considering the lack of existing data regarding the
long-term neurological consequences of consuming a soy-based
diet during infancy, particularly in children with developmen-
tal disabilities, alternative formulas should be considered when
clinically indicated.
HUMAN SUBJECTS
All studies conducted by the author in rodents or by retrospective
analyses of human medical record data were performed in accor-
dance with institutional and national guidelines and regulations.
The mouse studies were conducted under an approved University
of Wisconsin-Madison animal care protocol administered through
their Animal Resource Center. The institutional review protocol
governing the Simons Simplex collection was approved by the
Institutional Review Board at Columbia University Medical Cen-
ter. Written informed consent was provided by all guardians or
research subjects. The privacy of participants was protected by
using global unique identifiers. The research protocol for using
the Simons Simplex collection in the studies described herein was
approved by the Human Research Protection Program at the Uni-
versity of Wisconsin-Madison, which determined that the study
qualified for exemption.
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